Risk Algorithm Using Biomarker May Double Screen-Detected Ovarian Cancers
the Cancer Therapy Advisor take:
Screening through the use of a risk of ovarian cancer algorithm (ROCA) doubled the number of screen-detected primary invasive epithelial ovarian or tubal cancers (iEOCs), according to a recent study published online ahead of print in the Journal of Clinical Oncology.
Researchers led by Usha Menon, MD, of the University College London looked at patient data of 640 women from the United Kingdom Collaborative Trial of Ovarian Cancer Screening.
Among these women, all of whom underwent surgery, the researchers found that 133 had primary iEOCs, with 22 interval iEOCs occurring within one year of screening.
ROCA alone was able to detect 87.1 percent of the iEOCs, compared with fixed CA-125 cutoffs which would have identified 41.5 percent of women with more than 35 U/mL, 48.4 percent of more than 30 U/mL, and 66.5 percent of more than 22 U/mL.
“In the context of cancer screening, reliance on predefined single-threshold rules may result in biomarkers of value being discarded,” the authors concluded.
Screening through the use of a risk of ovarian cancer algorithm doubled the number of screen-detected cancers.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- Clinical Applications of Liquid Biopsies in Cancer
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Radical Prostatectomy Compared With Watchful Waiting in Localized Prostate Cancer
- Immunotherapy in Glioblastoma: Peaks and Pits
- OS and PFS End Points Not Met in Phase 3 Trial of Pembrolizumab in Advanced HCC
- No Benefit Observed With Osimertinib Plus Durvalumab in EGFR-Mutated NSCLC
- Evidence of the Role of Circulating Insulin in Renal Cell Carcinoma Risk
- Treatment Guidelines in Cancer: Assessing Industry Influence on Recommendations
- American Society of Breast Surgeons Recommends Genetic Testing for All Patients With Breast Cancer